免疫检查点抑制剂联合治疗：现状与新策略。
Immune checkpoint inhibitor combinations-current and emerging strategies.
机构信息
Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
出版信息
Br J Cancer. 2023 Apr;128(8):1415-1417. doi: 10.1038/s41416-023-02181-6. Epub 2023 Feb 6.
Abstract
In an attempt to overcome resistance to immune checkpoint inhibitors (ICI), an ever-increasing number of trials are exploring combination treatment approaches. Outcomes of a novel ICI doublet presented by Desai and colleagues are discussed along with emerging novel strategies and a view to future ongoing rational trial design maximising patient benefit.
摘要
为了克服对免疫检查点抑制剂（ICI）的耐药性，越来越多的试验正在探索联合治疗方法。Desai 及其同事提出的一种新型 ICI 双药治疗方案的结果，以及新出现的策略和未来正在进行的合理试验设计的观点，都旨在最大限度地提高患者的获益。
相似文献
1
Immune checkpoint inhibitor combinations-current and emerging strategies.免疫检查点抑制剂联合治疗：现状与新策略。
Br J Cancer. 2023 Apr;128(8):1415-1417. doi: 10.1038/s41416-023-02181-6. Epub 2023 Feb 6.
2
Development of Immunotherapy Combination Strategies in Cancer.癌症免疫疗法联合策略的发展。
Cancer Discov. 2021 Jun;11(6):1368-1397. doi: 10.1158/2159-8290.CD-20-1209. Epub 2021 Apr 2.
3
Immunotherapy combinations for the treatment of patients with solid tumors.免疫疗法联合治疗实体瘤患者。
Future Oncol. 2020 Aug;16(23):1715-1736. doi: 10.2217/fon-2020-0303. Epub 2020 Jun 5.
4
Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.提高免疫检查点抑制剂在晚期乳腺癌中疗效的新型联合策略。
Clin Transl Oncol. 2021 Oct;23(10):1979-1994. doi: 10.1007/s12094-021-02613-w. Epub 2021 Apr 19.
5
Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.当前前列腺癌免疫检查点抑制剂治疗的现状和未来展望：全面综述。
Int J Mol Sci. 2020 Jul 31;21(15):5484. doi: 10.3390/ijms21155484.
6
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?肝细胞癌中的双重免疫检查点阻断：我们目前的进展如何？
Future Oncol. 2022 Mar;18(8):1023-1034. doi: 10.2217/fon-2021-0905. Epub 2022 Feb 3.
7
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.肉瘤：免疫生物标志物表达和检查点抑制剂试验。
Cancer Treat Rev. 2020 Dec;91:102115. doi: 10.1016/j.ctrv.2020.102115. Epub 2020 Oct 20.
8
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.免疫检查点抑制剂与癌症治疗中抗生素相互作用的分析。
Front Med. 2022 Jun;16(3):307-321. doi: 10.1007/s11684-022-0927-0. Epub 2022 Jun 1.
9
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.免疫检查点抑制剂在结直肠癌治疗中的出现。
Curr Drug Targets. 2021;22(9):1021-1033. doi: 10.2174/1389450122666210204204415.
10
Immune checkpoint inhibitors in GBM.胶质母细胞瘤中的免疫检查点抑制剂
J Neurooncol. 2021 Oct;155(1):1-11. doi: 10.1007/s11060-021-03859-8. Epub 2021 Oct 1.
引用本文的文献
1
Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind?以新靶点推动免疫检查点抑制剂的进展：我们是过于“胆小”还是“滞后”了？
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf145.
2
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.嵌合抗原受体T细胞疗法在脑恶性肿瘤中的应用：细胞转运与存活面临的障碍
Front Immunol. 2025 Jun 19;16:1596499. doi: 10.3389/fimmu.2025.1596499. eCollection 2025.
3
Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function.免疫检查点抑制会扰乱神经免疫稳态并损害认知功能。
J Exp Clin Cancer Res. 2025 Jul 2;44(1):183. doi: 10.1186/s13046-025-03442-3.
4
Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy.利用液体活检揭示耐药机制并指导个性化免疫治疗。
Transl Oncol. 2025 Jun 24;59:102445. doi: 10.1016/j.tranon.2025.102445.
5
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.INBRX-106：一种六价OX40激动剂，通过优化受体聚集驱动卓越的抗肿瘤反应。
J Immunother Cancer. 2025 May 21;13(5):e011524. doi: 10.1136/jitc-2025-011524.
6
Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical Hodgkin lymphoma.固定低剂量纳武单抗与苯达莫司汀联合治疗高危复发/难治性经典型霍奇金淋巴瘤儿童患者
Br J Haematol. 2025 May 20;207(1):249-53. doi: 10.1111/bjh.20148.
7
Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines.托珠单抗调节效应细胞上的激活和抑制信号，增强其对CD318+肿瘤细胞系的细胞毒性。
Front Immunol. 2025 May 5;16:1585597. doi: 10.3389/fimmu.2025.1585597. eCollection 2025.
8
Exploiting pre-dormancy tumor immune microenvironment induced by androgen deprivation in prostate cancer.利用雄激素剥夺诱导的前列腺癌休眠前肿瘤免疫微环境。
Transl Cancer Res. 2025 Apr 30;14(4):2183-2187. doi: 10.21037/tcr-2024-2683. Epub 2025 Apr 15.
9
Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy.载有瑞喹莫德的热敏脂质纳米颗粒促进肿瘤相关巨噬细胞极化以增强膀胱癌免疫治疗
ACS Nano. 2025 Jun 3;19(21):19599-19621. doi: 10.1021/acsnano.4c17444. Epub 2025 May 17.
10
Immune Checkpoint Inhibition Perturbs Neuro-immune Homeostasis and Impairs Cognitive Function.免疫检查点抑制破坏神经免疫稳态并损害认知功能。
Res Sq. 2025 Apr 25:rs.3.rs-6389488. doi: 10.21203/rs.3.rs-6389488/v1.
本文引用的文献
1
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.癌症免疫治疗中的免疫检查点调节剂：最新进展和新兴概念。
J Hematol Oncol. 2022 Aug 17;15(1):111. doi: 10.1186/s13045-022-01325-0.
2
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.一项 MEDI0680 联合度伐利尤单抗对比纳武利尤单抗单药治疗晚期或转移性透明细胞肾细胞癌的随机 II 期研究。
Clin Cancer Res. 2022 Jul 15;28(14):3032-3041. doi: 10.1158/1078-0432.CCR-21-4115.
3
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.纳武利尤单抗联合伊匹单抗联合或不联合活菌制剂治疗转移性肾细胞癌的随机 1 期试验。
Nat Med. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28.
4
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.免疫检查点抑制剂联合疗法；新前沿。
Cancer Cell Int. 2022 Jan 3;22(1):2. doi: 10.1186/s12935-021-02407-8.
5
Development of Immunotherapy Combination Strategies in Cancer.癌症免疫疗法联合策略的发展。
Cancer Discov. 2021 Jun;11(6):1368-1397. doi: 10.1158/2159-8290.CD-20-1209. Epub 2021 Apr 2.
6
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.PD-L1 作为免疫检查点抑制剂反应的生物标志物。
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. doi: 10.1038/s41571-021-00473-5. Epub 2021 Feb 12.
7
Revisiting the PD-1 pathway.重新审视PD-1通路。
Sci Adv. 2020 Sep 18;6(38). doi: 10.1126/sciadv.abd2712. Print 2020 Sep.
8
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.随机 III 期 KEYNOTE-045 试验：帕博利珠单抗对比紫杉醇、多西他赛或长春氟宁在复发性晚期尿路上皮癌中的应用：超过 2 年随访结果。
Ann Oncol. 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127.
Zotero 插件